Silo Pharma Secures European Patent for Stress Disorder Prevention

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Apr 07 2026

0mins

SILO+16.12%

Should l Buy SILO?

Source: NASDAQ.COM

Patent Progress: Silo Pharma has received a patent allowance from the European Patent Office for an innovative approach to preventing stress-related disorders, marking a significant milestone in the biopharmaceutical sector that is expected to enhance its intellectual property portfolio and market competitiveness.
Therapeutic Potential: The patent focuses on preventing stress-induced fear and depressive behaviors through the 5-HT4 receptor pathway, representing a shift from symptom management to prevention, which could open new avenues in mental health treatment.
Diversified Pipeline: Silo Pharma is advancing several programs, including SPC-15 for PTSD, SP-26 for fibromyalgia, and SPC-14 for neuroinflammation, with multiple data releases expected in 2026, showcasing the company's extensive commitment to mental health.
Broad Market Outlook: With increasing global attention on mental health, Silo Pharma's patent allowance positions it to lead in CNS therapeutics, potentially reshaping how clinicians and patients approach the management of psychiatric disorders.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SILO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SILO

About SILO

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

SPC-15 PTSD Program Aligns with Federal Push for Mental Health Therapies

4 hours agoNewsfilter

Policy Acceleration: On April 18, 2026, President Trump signed an executive order directing multiple U.S. agencies to expedite research into psychedelic therapies for mental health, indicating a national focus that could create a more favorable regulatory environment for Silo Pharma's SPC-15 program.
Innovative Treatment Approach: SPC-15, designed as a novel 5-HT4 receptor agonist, targets prophylactic treatment for PTSD and utilizes rapid nose-to-brain delivery to enhance therapeutic effects and patient compliance, potentially revolutionizing mental health treatment outcomes.
Significant Market Opportunity: The global mental health therapeutics market is expanding, with PTSD affecting millions annually; the growing acceptance of psychedelic-assisted therapies may unlock new treatment paradigms and commercial opportunities, positioning Silo Pharma favorably in this evolving landscape.
Clear R&D Strategy: Silo Pharma has licensed intellectual property for SPC-15 from Columbia University and is preparing for FDA IND engagement, demonstrating a strategic focus on drug delivery and clinical development aimed at leveraging evolving regulatory frameworks to accelerate innovation.

Trump Signs Executive Order to Accelerate Psychedelic Research

3 hours agostocktwits

Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.

Silo Pharma Secures Patent for PTSD Therapy

Apr 07 2026stocktwits

Patent Grant: Silo Pharma has been awarded a patent for the application titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' further solidifying the company's position in the mental health market, which is considered a 'massive and underserved market.'
Market Reaction: Following the European Patent Office's indication to grant the patent, Silo Pharma's shares surged over 85% in premarket trading on Tuesday, reflecting strong investor confidence and market anticipation for the new therapy.
Innovative Therapy: This therapy differs from traditional PTSD treatments by focusing on enhancing stress resilience rather than managing symptoms post-trauma, indicating a strategic shift in the company's treatment approach that may attract more attention and investment.
Global IP Expansion: Silo Pharma described the patent grant as a 'high-value milestone' that will strengthen its global intellectual property position, aiding the company's efforts to maximize geographic coverage and long-term value.